ImmunoForge gets rights to PB1023 from PhaseBio
PhaseBio granted ImmunoForge exclusive, worldwide rights to develop and commercialize PB1023 for all indications except diabetes, obesity and non-alcoholic steatohepatitis (NASH).
ImmunoForge Co. Ltd. (Seoul, South Korea) will develop the compound for serious sarcopenia-related diseases...
BCIQ Company Profiles
BCIQ Target Profiles